IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs - PubMed

Affiliations

• PMID: 9605150

IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs

L H Wong et al. J Immunol. 1998.

Abstract

IFN-stimulated gene factor 3 (ISGF3) mediates transcriptional activation of IFN-sensitive genes (ISGs). The component subunits of ISGF3, STAT1alphabeta, STAT2, and p48-ISGF3gamma, are tyrosine phosphorylated before their assembly into a complex. Subsequently, the ISGF3 complex is translocated to the nucleus. We have recently established that the responsiveness of human melanoma cell lines to type I IFNs correlates directly with their intracellular levels of ISGF3 components, particularly STAT1. In the present study, we show that pretreating IFN-resistant melanoma cell lines with IFN-gamma (IFN-gamma priming) before stimulation with type I IFN also results in increased levels of ISGF3 components and enhanced DNA-binding activation of ISGF3. In addition, IFN-gamma priming of IFN-resistant melanoma cell lines increased expression of type I IFN-induced ISG products, including ISG54, 2'-5'-oligoadenylate synthase, HLA class I, B7-1, and ICAM-1 Ags. Furthermore, IFN-gamma priming enhanced the antiviral effect of IFN-beta on the IFN-resistant melanoma cell line, MM96. These results support a role for IFN-gamma priming in up-regulating ISGF3, thereby augmenting the responsiveness of IFN-resistant melanoma cell lines to type I IFN and providing a molecular basis and justification for using sequential IFN therapy, as proposed by others, to enhance the use of IFNs in the treatment of melanoma.

Similar articles

• Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

  Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ. Wong LH, et al. J Biol Chem. 1997 Nov 7;272(45):28779-85. doi: 10.1074/jbc.272.45.28779. J Biol Chem. 1997. PMID: 9353349

• Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).

  Chawla-Sarkar M, Leaman DW, Jacobs BS, Tuthill RJ, Chatterjee-Kishore M, Stark GR, Borden EC. Chawla-Sarkar M, et al. J Interferon Cytokine Res. 2002 May;22(5):603-13. doi: 10.1089/10799900252982089. J Interferon Cytokine Res. 2002. PMID: 12060499

• Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha.

  Li X, Leung S, Qureshi S, Darnell JE Jr, Stark GR. Li X, et al. J Biol Chem. 1996 Mar 8;271(10):5790-4. doi: 10.1074/jbc.271.10.5790. J Biol Chem. 1996. PMID: 8621447

• The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses.

  Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J, Bluyssen HA. Blaszczyk K, et al. Cytokine Growth Factor Rev. 2016 Jun;29:71-81. doi: 10.1016/j.cytogfr.2016.02.010. Epub 2016 Mar 18. Cytokine Growth Factor Rev. 2016. PMID: 27053489 Review.

• A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses.

  Michalska A, Blaszczyk K, Wesoly J, Bluyssen HAR. Michalska A, et al. Front Immunol. 2018 May 28;9:1135. doi: 10.3389/fimmu.2018.01135. eCollection 2018. Front Immunol. 2018. PMID: 29892288 Free PMC article. Review.

Cited by

• Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

  Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, Yu XZ. Yu Y, et al. J Immunol. 2013 Feb 15;190(4):1873-81. doi: 10.4049/jimmunol.1201989. Epub 2013 Jan 11. J Immunol. 2013. PMID: 23315072 Free PMC article.

• Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses.

  Wilmes S, Jeffrey PA, Martinez-Fabregas J, Hafer M, Fyfe PK, Pohler E, Gaggero S, López-García M, Lythe G, Taylor C, Guerrier T, Launay D, Mitra S, Piehler J, Molina-París C, Moraga I. Wilmes S, et al. Elife. 2021 Apr 19;10:e66014. doi: 10.7554/eLife.66014. Elife. 2021. PMID: 33871355 Free PMC article.

• Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responses.

  Messina NL, Clarke CJ, Johnstone RW. Messina NL, et al. JAKSTAT. 2016 May 18;5(1):e1173804. doi: 10.1080/21623996.2016.1173804. eCollection 2016. JAKSTAT. 2016. PMID: 27512617 Free PMC article.

• The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

  Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, Magro C, Durbin J, Carson WE 3rd. Lesinski GB, et al. J Clin Invest. 2003 Jul;112(2):170-80. doi: 10.1172/JCI16603. J Clin Invest. 2003. PMID: 12865406 Free PMC article.

• Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.

  Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, Walker MJ, Carson WE 3rd. Lesinski GB, et al. Cancer Immunol Immunother. 2005 Sep;54(9):815-25. doi: 10.1007/s00262-004-0649-y. Epub 2005 Jan 25. Cancer Immunol Immunother. 2005. PMID: 15668815 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal